North America Custom Antibody Services Market

North America Custom Antibody Services Market Outlook

The Food and Drug Administration (FDA) approves biosimilar products and provides the scientific and regulatory advice needed to introduce safe and effective biosimilars to the market. The approval of biosimilar products can improve patient care by increasing the number of medication options at potentially lower costs.

A few recent approvals of biosimilar products are mentioned below:

Biosimilars can reduce treatment costs and improve patient access to biologic therapies. In recent years, a vast range of biosimilars have been approved by the FDA. According to ScienceDirect.com, biosimilars can retain costs and expand the availability of monoclonal antibodies. Thus, the rising approvals of biosimilars fuel the growth of the custom antibody services market.

North America Custom Antibody Services Market Country Insights

Based on country, the North America custom antibody services market comprises the US, Canada, and Mexico. The US held the largest share in 2023.

In North America, the US is the largest contributor to the custom antibody services market. The growing incidences of infectious, chronic, and autoimmune diseases increase demand for custom antibody services in the US. Cancer occupies second place among the most prominent causes of death in the country. According to a study published in the American Cancer Society, more than 1.9 million new cases of cancer were diagnosed in the US in 2022, while ~609,360 patients succumbed to the disease. The country is likely to record ~2.0 million new cancer diagnoses in 2024. Custom antibodies are crucial in cancer treatment, aiding in detecting tumor-specific antigens and monitoring patient progress. Increased research and development efforts, and the rising adoption of custom antibodies in oncology, immunology, stem cell, infectious disease, neurobiology, and cardiovascular disease research further benefit the custom antibody services market in the US. Agathos Biologics, a leading biotechnology and genetic medicine company, launched its recombinant adeno-associated virus (rAAV) production service in March 2024 by using its new AE1-BHK cell line. The company made the first sale of rAAV to a contract research and manufacturing organization, Genovac, which discovers, manufactures, and develops antibodies for therapeutic, diagnostic, and research applications.

Many companies in the US are involved in the research and development related to antibody testing products. Thermo Fisher Scientific (US) collaborated with Wuxi and Mayo Clinic in 2020 to secure FDA authorization for testing samples with ELISA to detect IgM and IgG antibodies against SARS-CoV-2 antigens. Such collaborations between biotechnology companies propel the utilization of custom antibody services in clinical research.

North America Custom Antibody Services Market Company Profiles

Some of the key players operating in the market include Thermo Fisher Scientific Inc; Sino Biological Inc.; GenScript Biotech Corporation; Biochain Incorporated; R&D Systems, Inc; Kaneka Eurogentec S.A.; Fortis Life Sciences; Precision Antibody (A&G Pharmaceutical, Inc.; Biocytogen Pharmaceuticals Beijing Co Ltd; Abgenex; Creative Biolabs Inc; Agilent Technologies Inc; Bioklone; and Scantibodies Laboratory, Inc. among others. These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

North America Custom Antibody Services Market Research Methodology :

The following methodology has been followed for the collection and analysis of data presented in this report:

• Secondary Research

The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations.
• Industry trade journals and other relevant publications.
• Government documents, statistical databases, and market reports.
• News articles, press releases, and webcasts specific to companies operating in the market.

Note: All financial data included in the Company Profiles section has been standardized to USD. For companies reporting in other currencies, figures have been converted to USD using the relevant exchange rates for the corresponding year.

• Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research.
• Enhance the expertise and market understanding of the analysis team.
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects.

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, business development managers, market intelligence managers, and national sales managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise